mRNA Vaccine Reduces Melanoma Death or Recurrence Risk by 42%
A collaborative effort by Moderna and Merck has resulted in a breakthrough mRNA vaccine that, when combined with immunotherapy, reduces the risk of death or recurrence of melanoma by 42%. The vaccine, tested on over 1,100 patients, is a personalized treatment targeting unique mutations in each patient's tumor. The results, presented at the European Society of Medical Oncology conference, mark a significant advancement in melanoma treatment.60 sourcesSee all sources
